Abstract 1332: Cancer-Immu portal: An open resource for exploring immunotherapy-related multidimensional cancer genomic profiles

Abstract

Abstract Cancer immunotherapy that blocks immune checkpoint molecules, such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein-1 /ligand-1 (PD-1/PD-L1), has revolutionized anticancer therapy. Since the first approval of ipilimumab (anti-CTLA-4) for the treatment of unresectable or metastatic melanoma, FDA has granted dozens of approval of immune checkpoint blockade (ICB) drugs for many cancers, including non-small cell lung cancer, urothelial cancer, renal cell carcinoma, Hodgkin's lymphoma, head and neck cancer, microsatellite instability or mismatch repair deficient cancers, gastric cancer, colorectal cancer, hepatocellular carcinoma and Merkel cell carcinoma. Although patients with advanced-stage cancers have opportunity to get durable benefits from ICB treatment, only a minority of them responds to ICB, which highlights the need of the predictive biomarkers for guiding the selection of patients. Meanwhile, driven by the advances of technologies, such as next-generation sequencing and single-cell technologies, the field of immunotherapy-related cancer genomic is evolving rapidly, providing unprecedented opportunities to draw a comprehensive picture about immuno-genomic connection. In recent years, large amount of immuno-genomic data were generated, however, most of them are scattered in literatures and are not readily accessible to the community. To provide easy access to those valuable immuno-genomic datasets, we developed Cancer-Immu (http://bioinfo.vanderbilt.edu/database/Cancer-Immu/), which collected 2799 samples from 13 cancer types with both ICB response outcome and genomic profiling by either bulk sequencing or single-cell technologies Cancer-Immu allows interactive exploration of associations between ICB responsiveness and a variety of known and novel genomic features (genetic, transcriptomics, immune cell, and single cell populations) across multiple cancer types. Additionally, Cancer-Immu enables users to analyse their own datasets independently or co-analyse with existing data to identify and validate signatures of interest. Cancer-Immu, provides a platform for immunotherapy response evaluations, reduces barriers between researchers and complex genomic data, and facilitates discoveries in cancer immunotherapy, such as guiding combination treatments, repositioning existing drugs, and even developing novel agents. Citation Format: Jing Yang, Qi Liu, Yu Shyr. Cancer-Immu portal: An open resource for exploring immunotherapy-related multidimensional cancer genomic profiles [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1332.